ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ALX Oncology Holdings Inc.
NASDAQ:ALXOHealthcare · Biotechnology
+0.00%$1.22
AH$1.19-2.46%vs close
Mkt Cap$152.41M
Float111.51M
O/S124.92M
Vol
$ Vol
RVOL
Inst Own84.2%
SI5.4%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$101.69M
Total Assets$59.05M
Free Cash Flow-$84.35M
Debt & Equity
Debt 17%
Equity 83%
Total Debt$5.22M
Total Equity$25.98M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ALXO's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$59.05M
Liabilities$33.06M
Accounts Receivable$298K
Accounts Payable$4.91M
Inventory$0
PP&E (Net)$1.2M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.18M | $4.8M | $2.07M |
| YoY Growth | - | - | - | - | - | -75.4% | 132.0% | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $1.07M | $4.36M | $1.88M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $107K | $436K | $187K |
| Gross Margin | - | - | - | - | - | 9.1% | 9.1% | 9.0% |
| Research and Development | $77M | $116.37M | $141.79M | $98.4M | $60.17M | $28.96M | $16.31M | $11.27M |
| Selling, General, and Administrative | $23.85M | $26.09M | $28.48M | $29.04M | $23.39M | $14.81M | $3.31M | $2.6M |
| Other | $3.17M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $104.02M | $142.47M | $170.28M | $127.44M | $83.56M | $43.77M | $19.62M | $13.87M |
| Operating Income (EBIT) | -$104.02M | -$142.47M | -$170.28M | -$127.44M | -$83.56M | -$43.66M | -$19.18M | -$13.68M |
| Operating Margin | - | - | - | - | - | -3694.0% | -400.0% | -662.0% |
| Interest Expense | $1.6M | $1.73M | $1.56M | $238K | $13K | $811K | $21K | $0 |
| Interest Income | $3.96M | $9.37M | $10.65M | $4.28M | $91 | $0 | $0 | $0 |
| Other Income (Expense) | $2.33M | $7.62M | $9.47M | $4.02M | $71K | -$1.84M | -$26K | -$2K |
| Income Before Tax (EBT) | -$101.69M | -$134.85M | -$160.81M | -$123.42M | -$83.48M | -$45.5M | -$19.21M | -$13.69M |
| Income Tax Expense | $0 | $0 | $0 | $64K | -$21K | $241K | $34K | $45K |
| Net Income | -$101.69M | -$134.85M | -$160.81M | -$123.48M | -$83.46M | -$45.74M | -$19.24M | -$13.73M |
| Net Income Margin | - | - | - | - | - | -3869.7% | -401.2% | -664.3% |
| Supplementary Data | ||||||||
| EPS | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.79 |
| Diluted EPS | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.79 |
| Weighted Average OS | 53.66M | 52.17M | 42.99M | 40.70M | 40.31M | 39.84M | 21.95M | 21.95M |
| EBITDA | -$99.39M | -$132.25M | -$158.4M | -$122.84M | -$83.42M | -$43.46M | -$18.76M | -$13.26M |
| EBITDA Margin | - | - | - | - | - | -3676.9% | -391.1% | -641.3% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $16.37M | $17.57M | $22.41M | $48.82M | $363.67M | $434.22M | $9.02M | $8.26M |
| Short-Term Investments | $28.42M | $110.19M | $160.33M | $217.38M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $44.79M | $127.76M | $182.74M | $266.21M | $363.67M | $434.22M | $9.02M | $8.26M |
| Accounts Receivable | $298K | $892K | $0 | $0 | $0 | $0 | $536K | $932K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $5.64M | $5.7M | $5.92M | $4.76M | $0 | $0 | $0 | $0 |
| Total Current Assets | $50.73M | $134.35M | $188.66M | $270.97M | $367.02M | $435.99M | $9.81M | $10.21M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $1.2M | $9.63M | $10.84M | $9.81M | $3.47M | $52K | $860K | $956K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3.49M | $3.52M | $35.41M | $16.7M | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.63M | $267K | $7.64M | $9.01M | $9.69M | $10K | $7K | $0 |
| Total Long-Term Assets | $8.32M | $13.42M | $53.89M | $35.52M | $13.16M | $62K | $867K | $956K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $59.05M | $147.78M | $242.55M | $306.49M | $380.18M | $436.05M | $10.68M | $11.16M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $4.91M | $4.5M | $8.59M | $8.07M | $3.76M | $4K | $3.75M | $697K |
| Short-Term Debt | $5.22M | $435K | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $179K | $1K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $14.42M | $5.97M | $6.7M | $4.72M | $3.53M | $2.13M | $1.06M | $369K |
| Total Current Liabilities | $24.55M | $18.5M | $36M | $28.32M | $15.29M | $6.2M | $4.98M | $1.87M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $9.47M | $9.64M | $9.39M | $0 | $0 | $5.42M | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $135K | $136K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $8.51M | $1.03M | $1.22M | $5.31M | $1.84M | $5K | $412K | $0 |
| Total Long-Term Liabilities | $8.51M | $15.66M | $16.84M | $14.7M | $1.84M | $5K | $5.97M | $136K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $33.06M | $34.16M | $52.84M | $43.02M | $17.13M | $6.21M | $10.95M | $2.01M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $70.36M | $60.93M |
| Common Stock | $54K | $53K | $50K | $41K | $41K | $40K | $3K | $3K |
| Retained Earnings | -$722.82M | -$621.12M | -$486.27M | -$325.47M | -$201.99M | -$118.52M | -$72.78M | -$53.54M |
| Comprehensive Income & Other | $28K | $275K | $256K | -$845K | $0 | $0 | $0 | -$1.02M |
| Other Stockholders' Equity | $748.74M | $734.69M | $675.93M | $588.89M | $564.99M | $548.33M | $72.5M | $62.69M |
| Total Equity | $25.98M | $113.62M | $189.71M | $263.46M | $363.05M | $429.85M | -$276K | $9.15M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $59.05M | $147.78M | $242.55M | $306.49M | $380.18M | $436.05M | $10.68M | $11.16M |
| Supplementary Data | ||||||||
| Total Debt | $5.22M | $16.98M | $17.2M | $10.43M | $742K | $0 | $5.42M | $0 |
| Net Debt | -$11.16M | -$589K | -$5.21M | -$38.39M | -$362.93M | -$434.22M | -$3.6M | -$8.26M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$101.69M | -$134.85M | -$160.81M | -$123.48M | -$83.46M | -$45.74M | -$19.24M | -$13.73M |
| Depreciation & Amortization | $706K | $872K | $836K | $342K | $51K | $202K | $429K | $431K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $12.58M | $27.09M | $26.27M | $23.84M | $13.91M | $5.44M | $297K | $269K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $536K | $396K | -$932K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $421K | -$4.02M | $458K | $4.51M | $3.29M | -$3.74M | $2.98M | -$269K |
| Other Working Capital | -$85K | -$8.41M | $7.84M | $5.34M | -$7.32M | $3.46M | $885K | $1.04M |
| Total Working Capital Change | $336K | -$12.43M | $8.3M | $9.85M | -$4.03M | $247K | $4.26M | -$159K |
| Other Non-Cash Items | $3.93M | -$2.6M | -$4.96M | $228K | $5.42M | $1.57M | $11K | $0 |
| Net Cash from Operating | -$84.14M | -$121.91M | -$130.36M | -$89.22M | -$68.1M | -$38.29M | -$14.25M | -$13.19M |
| Investing Activities | ||||||||
| Capital Expenditures | -$212K | -$447K | -$1.27M | -$1.43M | -$666K | -$31K | -$353K | -$653K |
| Acquisitions | $0 | $0 | $0 | $234K | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$51.59M | -$107.41M | -$246.63M | -$376.79M | $0 | $0 | $0 | $0 |
| Sales of Investments | $134.39M | $194.11M | $292.56M | $142.8M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$234K | -$4.26M | $641K | $0 | $0 |
| Net Cash from Investing | $82.59M | $86.26M | $44.66M | -$235.42M | -$4.92M | $610K | -$353K | -$653K |
| Financing Activities | ||||||||
| Debt Repaid | $1.36M | $827K | $388K | -$9.61M | $281K | - | -$5.92M | - |
| Common Stock Issuance | $1.73M | $31.64M | $58.89M | $903K | $2.75M | $368.26M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$6K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $792K | -$655K | $0 | -$10.05M | $10K | $7K |
| Net Cash from Financing | $362K | $30.82M | $59.29M | $9.86M | $2.47M | $462.88M | $15.36M | $1K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$1.19M | -$4.84M | -$26.42M | -$314.78M | -$70.55M | $425.2M | $755K | -$13.84M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$84.14M | -$121.91M | -$130.36M | -$89.22M | -$68.1M | -$38.29M | -$14.25M | -$13.19M |
| Capital Expenditure | -$212K | -$447K | -$1.27M | -$1.43M | -$4.92M | -$31K | -$353K | -$653K |
| Free Cash Flow | -$84.35M | -$122.36M | -$131.64M | -$90.65M | -$73.02M | -$38.32M | -$14.6M | -$13.84M |
| Cash at Beginning | $17.63M | $22.47M | $48.89M | $363.67M | $434.22M | $9.02M | $8.26M | $22.1M |
| Cash at End | $16.44M | $17.63M | $22.47M | $48.89M | $363.67M | $434.22M | $9.02M | $8.26M |